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Objective: Strategies to improve cartilage repair tissue quality after bone marrow cell-based procedures
may reduce later development of osteoarthritis. Doxycycline is inexpensive, well-tolerated, and has been
shown to reduce matrix-metalloproteinases (MMPs) and osteoarthritis progression. This study tests the
hypotheses that doxycycline reduces MMP, enhances chondrogenesis of human bone marrow-derived
mesenchymal stem cells (hMSC), and improves in vivo cartilage repair.
Design: Ninety hMSC pellets were cultured in chondrogenic media with either 0-, 1- or 2-mg/mL doxy-
cycline. Pellets were evaluated with stereomicroscopy, proteoglycan assay, qRT-PCR, and histology.
Osteochondral defects (OCDs) were created in the trochlear grooves of 24-Sprague-Dawley rats treated
with/without oral doxycycline. Rats were sacriﬁced at 12-weeks and repair tissues were examined
grossly and histologically.
Results: hMSC pellets with 1-mg/mL (P ¼ 0.014) and 2-mg/mL (P ¼ 0.002) doxycycline had larger areas
than pellets without doxycycline. hMSC pellets with 2-mg/mL doxycycline showed reduced mmp-13
mRNA (P ¼ 0.010) and protein at 21-days. Proteoglycan, DNA contents, and mRNA expressions of
chondrogenic genes were similar (P > 0.05). For the in vivo study, while the histological scores were
similar between the two groups (P ¼ 0.116), the gross scores of the OCD repair tissues in doxycycline-
treated rats were higher at 12-weeks (P ¼ 0.017), reﬂective of improved repair quality. The
doxycycline-treated repairs also showed lower MMP-13 protein (P ¼ 0.029).
Conclusions: This study shows that doxycycline improves hMSC chondrogenesis and decreases MMP-13
in pellet cultures and within rat OCDs. Doxycycline exerted no negative effect on multiple measures of
chondrogenesis and cartilage repair. These data support potential use of doxycycline to improve cartilage
repair to delay the onset of osteoarthritis.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis is a leading cause of disability. Focal cartilage
injuries are known to accelerate the degeneration of surrounding
cartilage and to hasten the onset of osteoarthritis. Articular carti-
lage has limited capacity to repair following injury1,2. Microfracture
(bone marrow stimulation) is commonly used to treat focal carti-
lage injuries. This technique involves the recruitment of bone
marrow-derived mesenchymal stem cells (MSCs) to the defect area
to participate in cartilage repair. However, the resulting repair does
not restore hyaline articular cartilage, but instead results inC.R. Chu, Kaufmann Medical
15213, USA. Tel: 1-412-605-
C.R. Chu).
s Research Society International. Pformation of a mechanically inferior ﬁbrocartilaginous scar
tissue1,2. Therefore, clinical strategies are needed to improve the
type and quality of repair tissue following marrow stimulation
procedures to potentially delay or prevent the onset of
osteoarthritis.
Doxycycline is a widely available, inexpensive and well-tolerated
antibiotic that has a long clinical history in humans. In addition,
doxycycline has been effectively usedwith the tetracycline-inducible
generegulationsystemforcontrolledgene therapyapplications in the
articular joint as well as other organ systems across multiple animal
models3,4. Besides anti-microbial and transgene-inducing functions,
doxycycline may also have intrinsic beneﬁts to articular cartilage.
Prior studies have shown that the tetracycline-class of medications
has the ability to inhibit matrix-metalloproteinases (MMPs), with
doxycycline being the most studied for this purpose5e10.
MMPs are a family of zinc-dependent proteinases that differ
slightly in substrate speciﬁcity. They function in maintaining theublished by Elsevier Ltd. All rights reserved.
Fig. 1. Doxycycline increased MSC pellet area
Cross-sectional areas were measured from the hMSC pellets cultured in chondrogenic
media with 0-, 1-, or 2-mg/mL Dox for 14- and 21-days. Pellet area increased from 14- to
21-days in chondrogenic culture period (P ¼ 0.002). As well, the pellet area was
signiﬁcantly affected by the doxycycline concentration in the chondrogenic media
regardless of the timepoints (P ¼ 0.002): 0-mg/mL Dox pellets were smaller than the
1-mg/mL (P ¼ 0.014) and 2-mg/mL Dox pellets (P ¼ 0.002). There was no difference in
sizes between the 1- and 2-mg/mL Dox pellets (P ¼ 0.535). n ¼ 3/group.
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molecules, such as collagens and proteoglycans11. Down-regulation
of MMP increases the amount of collagens retained in the ECM9.
MMP is upregulated in arthritis and following cartilage
injury6,9,10,12,13. Among the MMP collagenases, MMP-1 (collage-
nase-1), -8 (collagenase-2), and -13 (collagenase-3) cleave inter-
stitial collagens10,14. MMP-13 is the most active for degradation of
collagen-II, and has therefore been implicated in arthritic disease
processes15,16. In transgenic mice models, overexpression of MMP-
13 has induced osteoarthritic changes16 while the absence of MMP-
13 inhibited cartilage erosion17.
Oral administration of doxycycline has been postulated to have
beneﬁcial effects on articular cartilage by inhibiting MMP, speciﬁ-
cally MMP-1, -3 (stromelysin), and -135e10,18. Doxycycline admin-
istration in vivo has been shown to decrease MMP levels in small
animal models, as well as in human osteoarthritic samples19,20.
When doxycycline was administrated prophylactically in animal
models, decreased MMP activity was correlated to reduced
proteoglycan loss from cartilage ECM, as well as to reduced
degenerative changes in the weight-bearing areas of articular
cartilage21,22. In a randomized, double-blinded, placebo-controlled
study evaluating the effects of doxycycline on the progression of
joint space narrowing in mildly arthritic knees, the doxycycline
treatment group had a decreased rate of narrowing by 40% at
16-months and 33% at 30-months as compared to placebo
(P ¼ 0.017)6. On the other hand, other animal studies have not
demonstrated any effect of doxycycline treatment on joint disease
and/or MMP activities23,24. Hence numerous studies exist on the
effect of doxycycline on cartilage degeneration, however with
conﬂicting results.
Fewer studies have evaluated the effect of doxycycline on
musculoskeletal repair processes. In a study using a rat lam-
inectomy defect model, rats that received intra-peritoneal doxy-
cycline showed enhanced wound healing, potentially due to
reduction of scar tissue formation25. In another study, oral doxy-
cycline was shown to inhibit MMP and improve and the strength of
rotator cuff repairs in rats19. This study found that the doxycycline
administered group had improved load to failure as well as greater
collagen organization compared to controls and correlated these
ﬁndings to a signiﬁcant decrease in MMP-13 activity. In contrast,
another study investigating the healing of Achilles tendon in rats
showed decreased strength of the repaired tendon in the doxycy-
cline group26. While the effects of doxycycline on musculoskeletal
tissue repair processes may be variable, its effect on cartilage repair
with MSCs as well as on MSC chondrogenesis is largely unknown.
This study was performed to test the hypotheses that doxycycline
reduces MMP expression, enhances human mesenchymal stem cell
(hMSC) chondrogenesis, and improves in vivo cartilage repair.
Methods
In vitro studies
hMSC chondrogenic differentiation
Ninety pellet cultures were prepared using human MSCs from
a single donor cultured to passage 3 according to previously
described procedures27. Brieﬂy, 2.5  105 hMSCs were pelleted by
centrifugation at 500g for 15-min. The resulting pellets were
cultured in 0.5-mL of pre-deﬁned chondrogenic medium contain-
ing high-glucose Dulbecco’s Modiﬁed Eagle Medium (DMEM,
Gibco), with 1% penicillin-streptomycin (Gibco), 107-M dexa-
methasone (SigmaeAldrich), 50-mg/mL L-ascorbic acid-2-
phosphate (SigmaeAldrich), 40-mg/mL proline (MP Biomedicals,
Solon, USA), and 1% BD ITS þ Premix (BectoneDickinson),
10-ng/mL transforming growth factor-beta 1 (TGF-b1, R&DSystems). The chondrogenic medium was supplemented with 0-,
1-, or 2-mg/mL of doxycycline: 30 pellets per each of doxycycline
concentrations. The pellets were incubated at 37C in 5% CO2 for 3-,
7-, 14-, or 21-days, and the media was refreshed every 2e3 days.Chondrogenic hMSC pellet assessments
Pellet area and histological evaluation
At 14- and 21-days of culture in chondrogenic media
supplemented with 0-, 1-, or 2-mg/mL doxycycline, three hMSC
chondrogenic pellets per group were analyzed grossly and for
cross-sectional areas. Macroscopic assessment was performed
using stereomicroscopy (MVX-10 MacroView Systems, Olympus)
equipped with a DP71 camera (Olympus). The pellet area was
measured using DP2-BSW software (Olympus). The pellets were
subsequently ﬁxed in 10% formalin and embedded in parafﬁn for
histological analyses. Five-mm cross-sections were stained with
0.1% Safranin-O/0.5% Fast green for sulfated glycosaminoglycan
(GAG) and alizarin-red for calcium28, and immunostained for MMP-
13 according to standard protocols. Brieﬂy for MMP-13 immuno-
histochemistry (IHC), sections were de-parafﬁned and rehydrated
via conventional methods. Antigen retrieval was performed by
heating and cooling the slides in 10-mM sodium citrate (pH 6.0)
with 0.05% Tween-20 buffer (SigmaeAldrich) for 20-min each at
85C and room temperature. The sections were then digested in
1-mg/mL hyaluronidase in 0.1-M sodium acetate buffer (both from
SigmaeAldrich) for 30-min in 37C. The sections were then blocked
with 10% goat serum (Vector Laboratories) and 1% bovine serum
albumin (BSA, Fisher Scientiﬁc) for 1-h. The sections were incu-
batedwith a rabbit polyclonal antibody against MMP-13 (Abcam) at
1:100 dilution in 1% BSA overnight at 4C. Endogenous peroxidase
was blocked using 0.3% hydrogen peroxide (Sigma) in tris-buffered
saline (TBS, Calbiochem) for 15-min at room temperature. The
slides were then treated with secondary goat polyclonal anti-rabbit
antibody (Abcam) in 1% BSA in 1:100 dilution for an hour, then
developed using ImmPACT AEC Peroxidase Substrate (Vector
Laboratories), according to the manufacturer’s instructions. The
slides were counterstained with hematoxylin (Vector Laboratories).
Images of all the stained sections were captured using TE-2000U
Eclipse microscope (Nikon) equipped with a DP71 camera. The
MMP-13 IHC images in Fig. 4 had the contrast increased by the
Fig. 2. Doxycycline did not interfere with GAG synthesis or MSC proliferation
in vitro
(A) Total GAG content per hMSC pellets showed increasing GAG content with longer
chondrogenic culture time (P < 0.001), with GAG content of the 7-day pellets signif-
icantly greater than those of the 3-day pellets (P < 0.001), those of 14-day pellets
signiﬁcantly greater than those of the 7-day pellets (P < 0.001), and those of 21-day
pellets signiﬁcantly greater than those of the 14-day pellet (P < 0.001). There was
no signiﬁcant effect of doxycycline concentration on the GAG content (P ¼ 0.412).
(B) Total DNA content per hMSC pellets showed signiﬁcant effect of chondrogenic
culture time on the DNA contents (P < 0.001): DNA content of the 3-day pellets were
signiﬁcantly lower than those of the 7- (P < 0.001), 14- (P < 0.001) and 21-day
(P ¼ 0.009) pellets. There was no difference in DNA content among 7-, 14-, and 21-
day pellets. As well, there was no signiﬁcant effect of doxycycline concentration on
the DNA content (P ¼ 0.314). (C) Normalized GAG content with respect to the DNA
content showed that there is signiﬁcant effect of chondrogenic culture time in the
normalized GAG content (P < 0.001); however, the effect of doxycycline concentration
was not signiﬁcant (P ¼ 1.000). n ¼ 3/group.
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and -negative cell contrast for print.
Biochemical analyses
After 3-, 7-, 14-, and 21-days of chondrogenic culture, three
hMSC pellets per group were washed with phosphate buffered
saline (PBS, Gibco) and each dry pellet was frozen at 80C until
biochemical analyses. Each frozen pellet was incubated overnight
in 0.25-mL papain buffer (50-mM sodium phosphate buffer
(SigmaeAldrich), 50-mM Ethylenediaminetetraacetic acid (EDTA,Gibco), 5-mM cysteine-HCl (SigmaeAldrich), and 0.5-mg/mL
papain (SigmaeAldrich)) in 60C shaking water bath (200-RPM).
The papain-digested pellets were vortexed. GAG content was
quantiﬁed using the standard dimethylmethylene blue (DMMB)
assay using VersaMax UVeVis spectrophotometer (Molecular
Devices), and DNA content was quantiﬁed using Quant-iT
PicoGreen dsDNA Reagent and Kits (Molecular Probes) per
manufacturer’s protocol using a VICTOR X3 Multilabel Plate
Reader (Perkin Elmer). The GAG/DNA ratios were calculated from
the results of the two assays.
Gene expression analyses
Three hMSC pellets per group at 3-, 7-, 14-, and 21-days of
chondrogenic culture were washed with PBS and frozen at 80C
until gene expression analyses. Total RNA was extracted from each
frozen pellets using TRIzol (Invitrogen). Brieﬂy, pellets in 0.3-mL
TRIzol were grinded using microtube pestles (USA Scientiﬁc), and
the ground pellet samples were homogenized using QIAshredder
columns (Qiagen). The lysate was incubated at room temperature
for 5-min, after which the contents were centrifuged at 12,000g
for 10-min at 4C. RNeasy Mini Kit (Qiagen) was used for the rest
of the RNA isolating process per manufacturer’s protocol. The pre-
designed human aggrecan, collagen-II, collagen-I, collagen-X,
mmp-13 and 18S TaqMan primers were purchased from Applied
Biosystems. Custom human sox-9 primers and probe29 and human
tgf-b receptor II primers (forward: TCCACGTGTGCCAACAACATC
AAC; reverse: TGCCACTGTCTCAAACTGCTCTGA) and FAM-labeled
probe (ACAACACAGAGCTGCTGCCCATTG) were purchased from
Integrated DNA Technologies. qRT-PCR reactions were done in
duplicate in 384-well plates in a total volume of 10-mL as previously
described29 using 2x real-time TaqMan PCRmaster mix with an ABI
PRISM 7700 Sequence Detection System (Applied Biosystems).
Relative expression levels normalized to 18S were calculated using
the 2DCt method.In vivo studies
Animal surgeries
All longitudinal animal experiments were performed following
a University of Pittsburgh Institutional Animal Care and Use
Committee (IACUC) approved protocol (Protocol No.1103868) using
the previously established OCD model30,31. Brieﬂy, OCD creation on
twenty-four 3-month old Sprague-Dawley rats (Harlan) was per-
formed under general gaseous anesthesia (Isoﬂurane, Phoenix
Pharmaceuticals). The knees were shaved and swabbed with
betadine and ethanol. A medial parapatellar approach was utilized
to access the stiﬂe joint. The patella was dislocated laterally and the
knee was ﬂexed to greater than 90 to deliver the femoral trochlea
into operative view. The trochlear groove was identiﬁed and the
midpoint of the trochlea, which was themidpoint in the superior to
inferior dimension at the center of the trochlear groove, was
marked. A 1.5-mm drill was used to create the OCD, at a depth of
1.0-mm. The subchondral bone was penetrated until bleeding bone
was identiﬁed. Sterile saline was used to gently irrigate the area to
remove any osteochondral fragments, and the incision was closed
in layers. The animals were placed in standard cages with full
access to food and water post-operatively. Subcutaneous bupre-
norphine (Reckitt Benckiser Healthcare) at 0.5-mg/kg dosage was
injected twice daily for the ﬁrst 2-days following surgery as post-
operative analgesia. There was one death associated with anes-
thesia complication. Hence, the number of animals per group in the
in vivo study were N ¼ 11 for No Doxycycline Control group and
N ¼ 12 for 12Week Doxycycline group. The animals received either
regular drinking water or 2-mg/mL doxycycline (SigmaeAldrich) in
Fig. 3. Doxycycline inhibited MMP-13 gene expression in vitro
Messenger RNA levels of chondrogenic inducers sox-9 and tgf-bRII, chondrogenic genes aggrecan and col-II, ﬁbrocartilage marker col-I, hypertrophic chondrocyte marker col-X, and
catabolic gene mmp-13. There was an increasing trend in sox-9, tgf-bRII, aggrecan, col-II, and col-X levels (P’s < 0.01), and a decreasing trend in col-I level (P ¼ 0.028) over
chondrogenic culture time. There was no signiﬁcant effect of doxycycline concentration on these gene expressions (P > 0.05). For mmp-13 level, there was an upward trend until
day-14, with mRNA level in the 14-day pellets signiﬁcantly higher than those of the 3-day (P < 0.001), and 7-day (P < 0.001) pellets. However, on day-21, there is a reduction in the
mRNA level from day-14 (P < 0.001). The mmp-13 mRNA levels on day-21 pellets were also signiﬁcantly different among different doxycycline concentrations: 2-mg/mL Dox pellets
had signiﬁcantly lower mmp-13 levels compared to 0-mg/mL Dox pellets (P ¼ 0.01). n ¼ 3/group.
H.H. Lee et al. / Osteoarthritis and Cartilage 21 (2013) 385e393388the drinking water. Doxycycline water was replaced daily to ensure
fresh supply of doxycycline.
Repair tissue assessments
Following sacriﬁce by carbon dioxide asphyxiation at 12-weeks
post-OCD, the joints were dissected and the repair tissues were
examined grossly and analyzed with the aforementioned stereo-
microscopy and camera, with and without India ink staining for
gross grading using the ICRS-cartilage repair assessment system
(Table I)32. The harvested femurs were then ﬁxed, decalciﬁed,Fig. 4. Doxycycline reduced MMP-13 deposition in vitro
Representative images of (A) Safranin-O Fast Green, (B) MMP-13 IHC, and (C) Alizarin-red
difference in staining intensities for Safranin-O Fast Green and Alizarin-red stainings among
MMP-13-positive cells for 14-day timepoint. However, more MMP-13-positive cells were fo
those cultured in 2-mg/mL Dox at 21-day timepoint.embedded in parafﬁn, and subsequently sectioned. The sections
were stained using traditional hematoxylin and eosin (H&E)
staining, as well as immunostained using rabbit polyclonal anti-
body against MMP-13. The stained sections were imaged using
DP71 camera and Eclipse TE2000-U microscope, and evaluated
using modiﬁed Holland histological scoring system (Table II)30.
Three independent blinded individuals graded both the gross and
sectioned histologic specimens, and the scores were averaged for
statistical analysis. For the estimate percentages of MMP-13-
positive cells, the sections from four selected knees from eachstainings of hMSC pellets at 20 (larger box) and at 4 (smaller inset). There was no
different doxycycline concentration groups at each timepoint. As well, no difference in
und in the periphery of the hMSC pellets cultured in 0- and 1-mg/mL Dox compared to
Table I
ICRS cartilage repair scoring system
Criterias Points Scores
Degree of defect
repair
In level with surrounding cartilage 4
75% repair of defect depth 3
50% repair of defect depth 2
25% repair of defect depth 1
0% repair of defect depth 0
Integration to
border zone
Complete integration with surrounding
cartilage
4
Demarcating border <1 mm 3
3/4 of repair tissue integrated, 1/4 with
a notable border >1 mm
2
1/2 of repair tissue integrated with surrounding
cartilage, 1/4 with a notable border >1 mm
1
From no contact to 1/4 of repair tissue
integrated with surrounding cartilage
0
Macroscopic
appearance
Intact smooth surface 4
Fibrillated surface 3
Small, scattered ﬁssures or cracks 2
Several, small or few but large ﬁssures 1
Total degeneration of defect area 0
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(magniﬁcation, 20). Positive and negative cells were counted
using ImageJ software (NIH), and percentages were calculated by
dividing the numbers of MMP-13-stained cells by the sum of theTable II
Modiﬁed Holland histological scoring system
Criteria Points Scores
Overall defect evaluation (throughout the entire defect depth)
Percentage ﬁlling with
neoformed tissue (%)
100 3
>50 2
<50 1
0 0
Subchondral bone evaluation
Percentage ﬁlling with
neoformed tissue (%)
100 3
>50 2
<50 1
0 0
Subchondral bone
morphology
Normal trabecular bone 4
Trabecular, with some compact bone 3
Compact bone 2
Compact bone and ﬁbrous tissue 1
Only ﬁbrous tissue or no tissue 0
Extent of neotissue
bonding with adjacent
bone
Complete on both edges 3
Complete on one edge 2
Partial on both edges 1
Without continuity on either edge 0
Cartilage evaluation
Morphology of neoformed
surface tissue
Extensively articular cartilage 4
Mainly hyaline cartilage 3
Fibrocartilage (spherical morphology
observed with >75% of cells)
2
Only ﬁbrous tissue (spherical
morphology observed with <75% of
cells)
1
No tissue 0
Thickness of neoformed
cartilage
Similar to the surrounding cartilage 3
Greater than surrounding cartilage 2
Less than the surrounding cartilage 1
No cartilage 0
Joint surface regularity Smooth, intact surface 3
Surface ﬁssures (<25% neosurface
thickness)
2
Deep ﬁssures (25e99% neosurface
thickness)
1
Complete disruption of the neosurface 0
Chondrocyte clustering None at all 3
<25% chondrocytes 2
25e100% chondrocytes 1
No chondrocytes present (no cartilage) 0numbers of MMP-13-stained and unstained cells. On average, 304
cells were counted per OCD repair tissue. The MMP-13 IHC images
in Fig. 6(C) had the contrast increased by the same value in Adobe
Photoshop CS4 to improve MMP-13-positive and -negative cell
contrast for print and cell counting.
Statistical analyses
All statistical analyses were conducted using Statistical Package
for Social Studies (SPSS) 17.0 for Windows (IBM). Small letter “n”
represents number of replicates in an independent in vitro study,
while big letter “N” represents independent number of animals in
the in vivo study. Assumptions of parametric datawere tested for allFig. 5. Doxycycline did not interfere with in vivo cartilage repair
(A) Representative images of repair tissues from No Doxycycline Control and 12 Week
Doxycycline groups evaluated using stereomicroscopy. (B) Gross grading of OCD repair
tissues using ICRS-cartilage repair assessment grades showed better repair tissue for
the 12 Week Doxycycline group (P ¼ 0.017), while (C) histological grading of OCD
repair tissues using the modiﬁed Holland’s scoring showed no difference between the
two groups. N ¼ 11e12/group.
Fig. 6. Doxycycline inhibited MMP-13 deposition in vivo
(A) Representative 4 (larger box) and 20 (smaller inset) images of MMP-13
immunohistochemical staining of repair tissues from No Doxycycline Control and
12 Week Doxycycline groups. (B) Median and interquartile range of percentage of
MMP-13-positive cells in different treatment groups. More MMP-13-positive cells were
found in the newly formed repair tissues of No Doxycycline Control group compared to
those of 12 Week Doxycycline group (P ¼ 0.029). N ¼ 4/group.
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homogeneity of variance with Levene’s tests. P-values of less than
0.05 were considered signiﬁcant, unless otherwise noted. In vitro
studies were repeated two times in triplicate (n ¼ 3), with data and
statistical analysis with n ¼ 3 reported as line graphs with
mean 95% conﬁdence intervals from a representative experiment
(Figs. 1e3). In vivo studies were conducted and data observed using
independent animals, with N ¼ 11 for No Doxycycline Control
group and N ¼ 12 for 12 Week Doxycycline group. All the data are
reported as boxplots with median as the horizontal bar, inter-
quartile range calculated using Tukey Hinge as the box, and the
lowest and highest values represented as whiskers [Figs. 5(BeC),
and 6(B)]. For comparison among three groups and multiple
timepoints for the in vitro data, two-way independent analysis of
variance (ANOVA) was used with doxycycline concentration and
timepoints as main independent variables. For variables that were
considered signiﬁcant, post-hoc Tukey was used to further evaluate
the data. For comparisons between two groups for the in vivo data,
Student’s t-test was used for parametric data [Fig. 5(B) and (C)] and
ManneWhitney U test was used for non-parametric data [Fig. 6(B)].
Results
Gross evaluation of hMSC chondrogenic pellets (Fig. 1)
The areas of hMSC chondrogenic pellets increased with
increasing concentrations of doxycycline (P ¼ 0.002) and withincreasing time in chondrogenic culture (P ¼ 0.002). The post-hoc
Tukey test revealed that the pellet areas at both 14- and 21-day
timepoints were signiﬁcantly larger for those cultured in 1-mg/mL
(P ¼ 0.014) and 2-mg/mL (P ¼ 0.002) of doxycycline compared to
those cultured without any addition of doxycycline. There was no
signiﬁcant difference in pellet areas between those cultured in
1- and 2-mg/mL doxycycline. The interaction effect between the two
main variables, doxycycline concentration and culture time, was
also non-signiﬁcant (P ¼ 0.377).
Biochemical analyses of hMSC chondrogenic pellets (Fig. 2)
Total GAG [Fig. 2(A)] and DNA [Fig. 2(B)] content per pellet
samples and their ratio [Fig. 2(C)] weremeasured and calculated on
3-, 7-, 14-, and 21-day-old chondrogenic pellets to analyze the
effect of doxycycline on hMSC chondrogenesis and proliferation/
viability. For all three outcome measures, there was a signiﬁcant
main effect of the time in chondrogenic culture (P < 0.001);
however, the main effect of doxycycline concentration and the
interaction effects were non-signiﬁcant. The post-hoc Tukey tests
for total GAG content and GAG/DNA ratio revealed signiﬁcant
differences of these outcome variables between all the different
timepoints (P < 0.001). On the other hand, the post-hoc Tukey test
for total DNA content showed signiﬁcant differences between day-
3 and day-7 (P < 0.001), -14 (P < 0.001), and 21 (P ¼ 0.009).
Gene expression analyses of hMSC chondrogenic pellets (Fig. 3)
Various mRNA levels were measured on 3-, 7-, 14-, and 21-day-
old chondrogenic pellets to analyze the effect of doxycycline on
hMSC chondrogenesis. The time in chondrogenic culture had
signiﬁcant effect on gene expressions for all the assayed genes: sox-
9 (P ¼ 0.001), tgf-bRII (P ¼ 0.003), aggrecan (P < 0.001), collagen-II
(P< 0.001), collagen-I (P¼ 0.028), collagen-X (P< 0.001), andmmp-
13 (P< 0.001). The main effect of doxycycline concentration as well
as interaction effects between the two main independent variables
were non-signiﬁcant for sox-9, tgf-bRII, aggrecan, collagen-II,
collagen-I, and collagen-X mRNA levels. For the mmp-13 gene
expression, on the other hand, there was a non-signiﬁcant main
effect of doxycycline concentration but a signiﬁcant interaction
effect between the time in chondrogenic culture and doxycycline
concentration (P ¼ 0.025). This indicates that the doxycycline
concentration affected mmp-13 mRNA level differently on various
chondrogenic culture timepoints. Speciﬁcally, mmp-13 levels for all
three doxycycline concentrations were similar for day-3, -7, and -14
hMSC pellets; however, they were different for day-21 pellets
(P ¼ 0.012). The 2-mg/mL Dox pellets had signiﬁcantly lower mmp-
13 mRNA level compared to 0-mg/mL Dox pellets (P ¼ 0.010).
Histological analyses of hMSC chondrogenic pellets (Fig. 4)
Safranin-O Fast Green staining of sulfated GAGs showed
increased amount of staining for 21- vs 14-day hMSC pellets
[Fig. 4(A)]. However, no differences in staining intensities were
appreciable among the three different doxycycline concentrations.
These results conﬁrm the biochemical analysis of total GAG content
[Fig. 2(A)]. The MMP-13 IHC showed similar MMP-13-positive cells
for all the groups at day-14 [Fig. 4(B)]. However, the MMP-13
staining intensities decreased for all three groups by day-21. In
addition, more MMP-13-positive cells were found in the 0- and
1-mg/mL doxycycline pellets. These MMP-13 IHC results at 14- and
21-day timepoints are in accordance with themmp-13mRNA result
in Fig. 3. As upregulation of MMP-13 in MSC chondrogenesis has
also been linked to terminal differentiation of hypertrophic chon-
drocytes23,33,34, alizarin-red staining was performed. However,
H.H. Lee et al. / Osteoarthritis and Cartilage 21 (2013) 385e393 391there were no positively stained pellets at either doxycycline
concentration at both 14- and 21-day chondrogenic culture time-
points [Fig. 4(C)].
Evaluation of OCD repair tissues (Fig. 5)
The OCD repair tissues from the 12 Week Doxycycline group
showed more complete repair tissue within the femoral trochlear
groove by gross inspection with stereomicroscopy [Fig. 5(A)]. The
animals that received doxycycline for 12-weeks post-op had higher
mean total ICRS-cartilage repair scores via gross stereomicroscopy
examination, reﬂecting better quality repairs than the No Doxycy-
cline Control group [Fig. 5(B), P ¼ 0.017]. Qualitative evaluation
using the modiﬁed Holland Histological scoring of the H&E-stained
OCD repair tissue showed similar scores between the two groups
[Fig. 5(C), P ¼ 0.116].
MMP-13 of OCD repair tissue (Fig. 6)
The repair tissues from No Doxycycline Control group showed
more MMP-13-positive cells compared to those of 12 Week Doxy-
cycline group [Fig. 6(A)]: No Doxycycline Control group had 80%
MMP-13-positive cells, whereas 12 Week Doxycycline group had
44% MMP-13-positive cells [Fig. 6(B), P ¼ 0.029]. This in vivo OCD
repair tissue MMP-13 content result correlates to the in vitro hMSC
pellet data [Fig. 4(B)].
Discussion
This study showed that doxycycline enhanced cartilage tissue
formation and decreased MMP-13 both in human MSC pellet
cultures and within rat osteochondral defects (OCDs). Using
multiple measures of chondrogenesis and cartilage repair, doxy-
cycline also did not appear to exert any negative effects on either
human MSC chondrogenesis in vitro or on rat OCD repair in vivo.
These data support further work in the potential use of doxycycline
to improve cartilage repair or as an adjunct to other treatment
strategies to delay or prevent the onset of osteoarthritis.
As a strategy to enhance MSC chondrogenesis to improve
cartilage repair, our laboratory has previously investigated gene
therapy using adeno-associated virus (AAV) to deliver therapeutic
proteins of interest to articular joints30. Intra-articular injection of
AAV has been used in clinical trials35, and our previous study
showed improved cartilage repair with use of hMSC transduced
with AAV-TGF-b1. Nonetheless, there are potential safety issues
concerning long-term or high-dose expression of transgenes. For
this reason, controllable vectors have been developed to limit
treatment time/dosage to the minimal needed to achieve thera-
peutic efﬁcacy. One novel system is the Tet-on promoter, in which
control is facilitated by using tetracycline-class drugs as activators
of the tetracycline response element (TRE)-promoter, stimulating
transgene expression only in the presence of the drug. Previous
studies in our laboratory have successfully modulated AAV-
transgene expression utilizing this system with oral administra-
tion of 2-mg/mL doxycycline3. The data from the current study
showing a potential positive effect of doxycycline without evidence
of negative effects on in vitro and in vivo chondrogenesis support
continued investigations into the use of TRE promoters for localized
gene therapy to enhance cartilage repair.
The doses of doxycycline used in this study were based on
evidence for bioavailability and bioactivity in previous studies by
several groups. Oral administration of doxycycline at 2-mg/mL has
been shown to result in signiﬁcant upregulation of doxycycline-
controlled transgene expression in various rodent models3,36. In
our previous study, 1-mg/mL doxycycline added to the culturemedia was adequate to induce transgene expression for AAV2-TRE-
Luciferase vectors from the transduced intra-articular cells3. The 1-
and 2-mg/mL doxycycline for the current in vitro and the 2-mg/mL
doxycycline in drinking water for the current in vivo studies
were based on these studies. Additionally, these concentrations
approximate the intra-articular synovial ﬂuid doxycycline
concentration achieved following oral doxycycline. One study, in
which male Sprague-Dawley rats of similar weights were fed
comparable dose of oral doxycycline in drinking water for 5-dayse
4-weeks, determined the serum doxycycline level to be 1.8-mg/
mL19. In a study where serum and synovial ﬂuid concentrations of
doxycycline were measured following oral administrations of
5-mg/kg twice a day in horses, it was determined that doxycycline
distributes well from serum into synovial ﬂuid37. Therefore, we
expect the synovial ﬂuid doxycycline concentration following oral
administration of 2-mg/mL doxycycline to be not too far away from
0 to 2-mg/mL range.
Addition of doxycycline to the drinking water is a simple and
effective method of drug administration3,19,26,36,38. However, there
is inherent variability with this method because free water intake
by individual animals is not well-controlled. It is also difﬁcult to
monitor total water intake to determine actual doxycycline intake.
The difﬁculty in controlling doxycycline intake through inclusion of
the medication in the drinking water may account for the variable
observations on the effects of doxycycline seen in this and other
studies. Future studies with intra-peritoneal injection of doxycy-
cline or oral administration as a pill or measured suspension will
likely improve understanding of doxycycline on musculoskeletal
tissue repair processes.
The in vitro studies where dosage could be controlled showed
that doxycycline has no toxic/inhibitory effect on multiple of
measures of MSC chondrogenesis. The in vitro data also showed
that doxycycline exhibited a dose dependent reduction of MMP-13
gene expression as well as protein expressions by day-21 of pellet
culture. This is consistent with the MMP-13 suppressing activity of
doxycycline found in other differentiated tissue types, such as
chondrocytes and synoviocytes7,9. However, doxycycline-mediated
inhibition of mmp-13 expression occurred earlier after 24-h of
doxycycline exposure in other studies on chondrocytes9,10. This
effect was observed at 21-days in our hMSC chondrogenic pellet
cultures. The inhibitory effect of doxycycline on mmp-13 gene
expression may potentially be speciﬁc to differentiated cell types,
and not in multi-lineage state MSCs. The hMSC pellets are not of
chondrogenic phenotype initially. As such, inhibition of MMP-13
may have been observable only after chondrogenic differentiation
of the MSC cells.
In regards to in vitro chondrogenesis of human MSC, the pellet
areas in the 2-mg/mL doxycycline group were larger than those in
no doxycycline treatment group. Because we did not ﬁnd any
differences in aggrecan and col-II mRNA expression levels among
pellets cultured in different doxycycline concentrations, this effect
is more likely due to improved matrix retention through inhibition
of MMP-13 production. As MMP-13 primarily functions to break
down collagen-II7,23, MMP-13 down-regulation would ultimately
lead to reduction of excessive collagen-II degradation or enhance-
ment of collagen-II accumulation. MMP-13 is also a marker of
terminal differentiation of MSCs into hypertrophic chon-
drocytes23,33,34. However, lack of differences in col-X gene expres-
sion level and lack of alizarin-red positive staining among hMSC
pellets cultured in various doxycycline concentrations suggest that
doxycycline is not principally involved in inhibition of MSC
hypertrophy.
Our in vivo data additionally suggests that oral administration of
doxycycline has no harmful effect but may improve cartilage repair.
While we performed in vitro studies using human MSC to improve
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order to investigate the effects of doxycycline on host bonemarrow
repair cells accessed through OCD creation. This was performed to
enhance the clinical relevance by more closely mimicking the ex-
pected cellular repair processes occurring in bone marrow stimu-
lation procedures, such asmicrofracture, thanwhat can be achieved
through implantation of hMSC into OCDs created in athymic
rodents30. The OCD repair tissues from 12Week Doxycycline group
were of similar quality histologically and higher quality grossly vs
that from No Doxycycline Control group. As well, MMP-13
expression in OCD repair tissue samples was signiﬁcantly greater
in No Doxycycline Control than in 12 Week Doxycycline groups.
This can potentially explain the higher quality repairs reﬂected in
the ICRS scores in the doxycycline-treated rats. Furthermore, this
in vivo ﬁnding is correlated to the in vitro ﬁndings of MMP-13 levels
in control vs doxycycline-treated MSC pellets.
In summary, we showed in both in vitro and in vivo studies that
doxycycline had no toxic or inhibitory effect on MSC chondro-
genesis and cartilage repair. Furthermore, doxycycline inhibited
MMP-13 and potentially improved in vitro chondrogenesis and
in vivo cartilage repair. These ﬁndings suggest that doxycycline can
be used for external control of transgene expression in cartilage
repair studies incorporating AAV-mediated gene therapy strategies
without interfering with the repair process. Doxycycline inhibition
of MMP-13 may also serve to potentially improve in vivo cartilage
repair when used alone. As such, continued evaluation of doxycy-
cline effects on articular cartilage and MSC based tissue repair
processes may lead to readily implementable new treatment
strategies to delay the development of osteoarthritis through
improving cartilage repair processes.
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